CClinicalTrials.gg
Status unknownNCT03401008AcroDentUpdated Jan 17, 2018

Buccodental Manifestations in Patients With Acromegaly

An observational study in Acromegaly, sponsored by University Hospital, Clermont-Ferrand. Status unknown at 1 site in France. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2018-01-17.

Sponsored by University Hospital, Clermont-Ferrand · Observational

The sponsor has not verified this record recently (last verified Jan 2018), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
70
Ages
18 Years to 90 Years
Sex
All
01

Study summary

Context: Acromegaly is the rare condition (3 to 4 new cases per million per year) due to Growth Hormone (GH) overproduction by a somatotrope pituitary adenoma, resulting in Insulin Growth Factor 1 (IGF-1) excess. Consequently, many tissues of the organism become hypertrophied. Hypertrophy of gingival and dental tissues can lead to alteration of oral health. However, there are very few published data concerning oral impact of acromegaly.

Objective: To do the most accurate clinical and radiological state of oral manifestations in the series of prevalent acromegaly patients followed in the endocrinology service of the CHU of Clermont-Ferrand.

Read the detailed description

Context/ study relevance: Acromegaly is a rare condition (3 to 4 new cases per million per year) due to Growth Hormone (GH) overproduction by a somatotrope pituitary adenoma, resulting in Insulin Growth Factor 1 (IGF-1) excess. Consequently, a dysmorphic syndrome prevailing at the level of face and extremities progressively develops associated with potentially severe general manifestations (cardiovascular, respiratory and metabolic complications). Oral manifestations of acromegaly are not well known, there is very few published data on this topic and a controversy about the existence of a parodontal disease, i.e. the presence of gingival sulcus deepening which can lead to tooth loss. IGF-1 excess could lead to gingival hypertrophy and then to gingival sulcus deepening. Otherwise, the dental cementum, the only dental tissue which can grow during all lifetime, could be influenced by an excess of IGF-1. It is likely that acromegaly is associated with pathological cementum hypertrophy.

Objective: To do the most accurate clinical and radiological state of oral manifestations in the series of prevalent acromegaly patients followed in the endocrinology service of the CHU of Clermont-Ferrand. Investigator will take a special interest in parodontal status i.e. the state of supporting tissues of the teeth and structural anomalies of dental cementum.

As secondary objective, investigator would make a histological characterization of gingival and dental (cementum) tissues when a surgical treatment of the oral condition is required. Investigator will search hypertrophic anomalies linked with GH/IGF-1 excess.

Material and methods: This is an observational, descriptive, cross-sectional, monocentric study conducted in the endocrinology/diabetology service of Clermont-Ferrand University Hospital (CHU), in France, where a series of about 70 prevalent acromegaly patients is annually followed. The participants will be adult acromegaly patients followed in this service, with proven diagnosis of acromegaly or previous acromegaly. They will be excluded of the study if they are totally toothless, if they take a medication associated with gingival hypertrophy if they are in a medical or chirurgical condition interacting with oral health so that the oral evaluation is not reliable or if there is no possibility of written informed consent. For each participant, investigator will collect demographic data and history of the pathology including previous and actual complications, biological tests results, imaging exams results and treatments. The participants will answer 3 questionnaires: AcroQol (quality of life in acromegaly patients), GOHAI (General Oral Health Assessment Index) and EPICES (evaluation of precariousness). The primary outcome will be a quantitative assessment of the oral health of the acromegalic patients with detailed assessment of 3 criteria:

  • Depth of gingival sulcus measured for of all teeth
  • CAO index (number of teeth with cavity or obturation or missing)
  • Thickness of dental cementum on orthopantomogram and all other abnormality on this exam.

The secondary outcome will be the histological analysis of gingival and dental tissues if available.

All these measures will be taken during a routine odonto-stomatological consultation, part of the annual pathology evaluation at the endocrinology/diabetology service.

02

Conditions studied

  • Acromegaly

Browse trials for

Keywords

  • Acromegaly
  • Oral manifestations
03

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

acromegalic patients

Inclusion criteria

  • Adult acromegal patient followed in the endocrinology/diabetology service of the CHU of Clermont-Ferrand
  • Proven diagnosis of acromegaly or previous acromegaly

Exclusion criteria

Exclusion Criteria:

  • Minor subject
  • Subject under guardianship or curatorship
  • Total toothless patients
  • No possibility of written informed consent
  • Medical or chirurgical conditions interacting with oral health so that the oral evaluation is not reliable
  • Medication associated with gingival hypertrophy
04

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
70 participants (estimated)
Patient registry
No

Groups and cohorts

  • Acromegalic patients

    patients with a proven diagnosis of acromegaly achieved by an IGFA assay and a GH measure.

    Other: Oral manifestations

Interventions

  • OtherOral manifestations

    To do the most accurate clinical and radiological state of oral manifestations in the series of prevalent acromegaly patients followed in the endocrinology service of the CHU of Clermont-Ferrand.

05

What researchers measure

Primary outcomes

  1. oral health of acromegal patients

    the periodontal status would be determinate by measuring the depth of gingival sulcus with a graduated periodontal probe on the four dental faces (mesial, distal, vestibular and lingual), on each tooth present in the mouth.

    Time frame: at day 1 (during the odonto-stomatological consultation)

Secondary outcomes

  1. study of the dental cementum

    the thickness of dental cementum would be measured on orthopantomogram. This characteristic could determinate the presence or not of hypercementosis

    Time frame: at day 2 (24h after receipt of sample)

  2. Determinate the CAO index

    The CAO index could be determinate by counting the number of teeth with cavity or obturation or missing

    Time frame: at day 2 (24h after receipt of sample)

  3. Analysis of pathological gingival tissues

    : if a gingival hypertrophy is determinate, a gingivectomy will be carried out and the tissue will be sent to the Anatomo-pathology laboratory to determinate its histological characteristics

    Time frame: at day 2 (24h after receipt of sample)

06

Study locations

1 of 1 sites recruiting
  • CHU Clermont-Ferrand
    Clermont-Ferrand, 63003, France
    Recruiting
07

Registry details

Key details

Study ID
NCT03401008
Lead sponsor
University Hospital, Clermont-Ferrand
Responsible party
Sponsor
First posted
Jan 17, 2018
Start date
Dec 15, 2016
Primary completion
Dec 30, 2018 (estimated)
Completion
Mar 30, 2019 (estimated)
Last update
Jan 17, 2018

Study contacts

Patrick LACARIN
Contact
placarin@chu-clermontferrand.fr
0473751195
Igor TAUVERON
principal investigator · University Hospital, Clermont-Ferrand

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion